Viatris' research and development expenses 2016-2023
In 2023, Viatris spent over 800 million U.S. dollars on research and development. Operating expenses for research and development have steadily decreased until 2020, but increased again for the first time in 2021. This statistic shows the expenses for research and development of pharmaceutical company Viatris from 2016 to 2023.
Viatris is a global healthcare company headquartered in the United States with global centers in Pennsylvania, Shanghai and Hyderabad, India. The company was formed in November 2020 through the combination of Mylan and the Upjohn Business (owned by Pfizer Inc.). Its global portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized iconic brands (such as Viagra, Xanax, Lipitor).
Viatris is a global healthcare company headquartered in the United States with global centers in Pennsylvania, Shanghai and Hyderabad, India. The company was formed in November 2020 through the combination of Mylan and the Upjohn Business (owned by Pfizer Inc.). Its global portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized iconic brands (such as Viagra, Xanax, Lipitor).
